Cyclotherapy: exploiting cell-cycle decoupling for selective cancer cytotoxicity and normal-tissue protection

Area of Science:

• Oncology
• Pharmacology
• Cell Biology

Background:

• Cytotoxic anticancer agents damage both cancerous and healthy proliferating cells, limiting treatment efficacy.
• Cyclotherapy seeks to improve the therapeutic index by cell-cycle arrest, protecting normal cells from chemotherapy.
• Early cyclotherapy approaches faced translational challenges, but recent CDK4/6 inhibitors show promise.

Purpose of the Study:

• To review the biological rationale, preclinical evidence, and clinical progress of cyclotherapy.
• To analyze the successes and limitations of past and current cyclotherapy strategies.
• To propose a framework for future cyclotherapy development.

Main Methods:

• Review of existing literature on cyclotherapy, including early p53 activation and MDM2 inhibition studies.
• Examination of recent clinical data, particularly involving CDK4/6 inhibitors like trilaciclib.
• Analysis of factors influencing cyclotherapy efficacy, such as tumor-specific vulnerabilities and drug scheduling.

Main Results:

• Trilaciclib represents the first clinically approved pharmacologic myeloprotection for small-cell lung cancer.
• Cyclotherapy efficacy is context-dependent, influenced by tumor cell-cycle vulnerabilities (e.g., RB1 loss) and scheduling.
• Inconsistent results across tumor types highlight the need for refined patient stratification.

Conclusions:

• Cyclotherapy is an evolving paradigm, not a failed concept, requiring biological stratification and temporal optimization.
• A proposed framework emphasizes tumor sensitivity, toxicity dependency, and drug phase specificity for rational development.
• Refined cyclotherapy approaches may redefine cytoprotection and expand therapeutic options in oncology.